Management of atrial fibrillation – first European guidelines. What’s new? Review article
Article Sidebar
Main Article Content
Abstract
Proper management in atrial fibrillation plays a major role in prevention of heart failure and cardiovascular events. In this article author reviews 2010 Guidelines for the Management of Atrial Fibrillation prepared by The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), in the context of coexisting cardiovascular risk factors. The reason for updating guidelines are increasing prevalence of atrial fibrillation, availability of outcomes of new researches and metaanalysis as well as development of new drugs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Hohnloser S.H., Crijns H.J.G.M., van Eickels M. et al.: Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. N. Engl. J. Med. 2009; 360: 668-678.
3. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.